AMENDMENTS TO THE CLAIMS

1 – 10 (Cancelled)

11 (New). Pharmaceutical composition for veterinary use comprising an aqueous injectable suspension comprising a concentration of up to 500mg/ml sterile and micronised florfenicol or a substantially water-insoluble complex, co-crystal or salt thereof.

12 (New). The composition of claim 10, wherein the florfenicol is present as such and more than 95% of the total volume of the florfenicol are particles with a particle size smaller than 200 μm.

13 (New). The composition of claim 12 wherein the suspension has a continuous phase which contains 1 to 250 mg/ml of a buffer providing a pH-value in the range of 5 to 8.

14 (New). The composition of claim 13 wherein the suspension contains 10 to 400mg/ml of at least one stabilizer selected from the group consisting of a sugar, polyhydric alcohol, sugar acid, uronic acid and fruit acid having at least 3 functional hydroxy or carboxy groups or combination thereof, or a salt thereof.

15 (New). The composition of claim 14, comprising 0.1 to 10 mg/ml of sodium carboxymethylcellulose.

16 (New). The composition of claim 15, comprising 0.3 to 30 mg/ml of at least one injectable grade polyvinylpyrrolidone.

17 (New). The composition of claim 16, comprising a phospholipid surface-active agent at a concentration of 0.1 to 50 mg/ml or at least one different non-ionogenic surface active agent at a concentration of 1 to 30 mg/ml, or both.

18 (New). The compositions of claim 17, further comprising at least one antioxidant or synergist thereof, and antimicrobial preservative.

19 (New). The composition of claim 18, disposed in an aseptically filled sterile primary packing material.

20 (New). The composition of claim 19, wherein the phospholipid surface-active agent is disposed as a coating on the particles.

21 (New). The composition of claim 20, wherein at least 90% of the volume of the particles have a particle size between 0.5 and 200 μm, the buffer is present in an amount of 50 to 250 mg/ml and provides a pH between 5 and 7, the amount of stabilizer is between 50 and 300 mg/ml, the amount of polyvinylpyrrolidone is between 1 and 10 mg/ml, and the amount of antioxidant or synergist thereof is between 0.1 and 40 mg/ml.

22 (New). The composition of claim 21, wherein at least 90% of the volume of the particles have a particle size between 1 and 100 μm, and the polyvinylpyrrolidone has a K-value between K 12 and K 32.

23 (New). The composition of claim 22, wherein at least 90% of the volume of the particles have a particle size between 1 and 50 μm, and the polyvinylpyrrolidone has a K-value between K 12 and K 15.

24 (New). The composition of claim 23, disposed in an aseptically filled sterile primary packing material.

25 (New). The composition of claim 11 wherein the suspension has a continuous phase which contains 1 to 250 mg/ml of a buffer providing a pH-value in the range of 5 to 8.

26 (New). The composition of claim 11 wherein the suspension contains 10 to 400mg/ml of at least one stabilizer selected from the group consisting of a sugar, polyhydric alcohol, sugar acid, uronic acid and fruit acid having at least 3 functional hydroxy or carboxy groups or combination thereof, or a salt thereof.

27 (New). The composition of claim 11, comprising 0.1 to 10 mg/ml of sodium carboxymethylcellulose.

28 (New). The composition of claim 11, comprising 0.3 to 30 mg/ml of at least one injectable grade polyvinylpyrrolidone.

29 (New). The composition of claim 11, comprising a phospholipid surface-active agent at a concentration of 0.1 to 50 mg/ml, either coated on the particles or dispersed into the continuous phase or at least one different non-ionogenic surface active agent at a concentration of 1 to 30 mg/ml, or both.

30 (New). The compositions of claim 11, further comprising at least one antioxidant or synergist thereof, and antimicrobial preservative.